Form 4: Kristina Burow, Director at Boundless Bio, Reports Acquisition of Stock Options

Kristina Burow, a Director at Boundless Bio, filed a Form 4 disclosing the acquisition of 26,438 stock options on March 27, 2024.

Summary

• On March 29, 2024, Kristina Burow, a Director of Boundless Bio, Inc. [BOLD], filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 27, 2024, where Ms. Burow acquired 26,438 stock options.
• These options have an exercise price of $16.
• The stock options vest in 36 substantially equal monthly installments beginning on April 27, 2024, and expire on March 26, 2034.
• Following the reported transaction, Ms. Burow directly owns 26,438 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which is a common practice.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director can signal confidence in the company's future, potentially impacting shareholder sentiment positively.

Key Dates